Trial · NCT03066830
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 | Placebo | 0.06 | Standard Error 0.082 | percentage HbA1c | |
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 | Sotagliflozin 400 mg | -0.70 | Standard Error 0.068 | percentage HbA1c | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Placebo | 0.277 | Standard Error 0.2691 | millimole per liter (mmol/L) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Sotagliflozin 400 mg | -1.331 | Standard Error 0.1844 | millimole per liter (mmol/L) | |
| Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg | Placebo | -3.58 | Standard Error 1.052 | mmHg | |
| Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg | Sotagliflozin 400 mg | -4.41 | Standard Error 1.061 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Placebo | -0.69 | Standard Deviation 0.826 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Sotagliflozin 400 mg | -1.71 | Standard Deviation 0.830 | mmHg | |
| Change From Baseline in Body Weight at Week 26 | Placebo | -0.29 | Standard Deviation 0.206 | kilogram (kg) | |
| Change From Baseline in Body Weight at Week 26 | Sotagliflozin 400 mg | -1.70 | Standard Deviation 0.215 | kilogram (kg) | |
| Percentage of Participants With HbA1c <6.5% at Week 26 | Placebo | 1.6 | percentage of participants | ||
| Percentage of Participants With HbA1c <6.5% at Week 26 | Sotagliflozin 400 mg | 8.3 | percentage of participants | ||
| Percentage of Participants With HbA1c <7.0% at Week 26 | Placebo | 8.7 | percentage of participants | ||
| Percentage of Participants With HbA1c <7.0% at Week 26 | Sotagliflozin 400 mg | 26.1 | percentage of participants | ||
| Percentage of Participants With Hypoglycemic Events | Placebo | Any hypoglycemia | 22.1 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 400 mg | Any hypoglycemia | 19.7 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Placebo | Documented symptomatic hypoglycemia | 13.0 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 400 mg | Documented symptomatic hypoglycemia | 11.4 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Placebo | Severe or documented symptomatic hypoglycemia | 13.0 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 400 mg | Severe or documented symptomatic hypoglycemia | 11.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03066830/results